CEL-SCI Corporation
CVM
CEL-SCI Corporation engages in the research and development of immunotherapy for the treatment of cancer and infectious diseases. The company's lead investigational immunotherapy is Multikine, which is under phase III clinical trial for the treatment of head and neck cancer. Its Ligand Epitope Antigen Presentation System (LEAPS), a pre-clinical patented T-cell modulation process that stimulates thā¦ read more
Healthcare
Biotechnology
42 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$1.16
Price-4.92%
-$0.06
1Y
Price
Market Cap
$7.971m
Small
Price/Earnings 3y Avg5y Avg
-
Premium
Premium
Financial Reports
Key metrics over the past few years and other important metrics. Amounts in USD.-
EBITDA Margin-
Net Profit Margin-
Free Cash Flow Margin-
EBITDA Margin-
Net Profit Margin-
Free Cash Flow MarginRevenue
$0.00
-
1y CAGR-
3y CAGR-
5y CAGREarnings
-$22.701m
+5.6%
1y CAGR+12.6%
3y CAGR+10.0%
5y CAGREPS
-$3.47
+26.4%
1y CAGR+27.6%
3y CAGR+22.5%
5y CAGRBook Value
$6.875m
$17.707m
Assets$10.833m
Liabilities$8.512m
DebtDebt to Assets
48.1%
-0.5x
Debt to EBITDAFree Cash Flow
-$16.660m
+8.4%
1y CAGR+1.4%
3y CAGR+9.1%
5y CAGRNo items found.
Press Releases
Statements and updates from the company